Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects
There has been growing interest in nanoparticles as an approach to formulate poorly soluble drugs. Besides enhanced dissolution rates, and thereby, improved bioavailability, nanoparticles can also provide targeting capabilities when injected intravenously. The latter property has led to increased re...
Gespeichert in:
| Veröffentlicht in: | Advanced drug delivery reviews 2008-05, Vol.60 (8), p.939-954 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 954 |
|---|---|
| container_issue | 8 |
| container_start_page | 939 |
| container_title | Advanced drug delivery reviews |
| container_volume | 60 |
| creator | Wong, Joseph Brugger, Andrew Khare, Atul Chaubal, Mahesh Papadopoulos, Pavlos Rabinow, Barrett Kipp, James Ning, John |
| description | There has been growing interest in nanoparticles as an approach to formulate poorly soluble drugs. Besides enhanced dissolution rates, and thereby, improved bioavailability, nanoparticles can also provide targeting capabilities when injected intravenously. The latter property has led to increased research and development activities for intravenous suspensions. The first intravenously administered nanoparticulate product, Abraxane® (a reformulation of paclitaxel), was approved by the FDA in 2006. Additional clinical trials have been conducted or are ongoing for multiple other indications such as oncology, infective diseases, and restenosis. This article reviews various challenges associated with developing intravenous nanosuspension dosage forms. In addition, various formulation considerations specific to intravenous nanosuspensions as well as reported findings from various clinical studies have been discussed. |
| doi_str_mv | 10.1016/j.addr.2007.11.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69141129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X08000471</els_id><sourcerecordid>19908030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-3dc1f9fe6e38499eb6cf86bd6441603f196ee0554dd92768ed7c40cdd739a7f3</originalsourceid><addsrcrecordid>eNqFkUFrFDEYhoModq3-AQ-Skyg403xJJpMUL6WoLRQ8tIi3MJt8gSyzmTGZXem_N8su9GZPIcnzvfC9DyHvgbXAQF1s2sH73HLG-hagZUy_ICvQPW80N_IlWVXINJKZ32fkTSkbxoD3ir0mZ6CFFB3vVwTvd2XGVOKUCg1TpjEtedhjmnaFfrr99bk-bNAt9f-SXtGM-4h_6RSoxz2O07zFtHyhc0Y3xhTdMNIhefp0qeFuKW_JqzCMBd-dznPy8P3bw_VNc_fzx-311V3jpOZLI7yDYAIqFFoag2vlglZrr6QExUQAoxBZ10nvTd1Eo--dZM77XpihD-KcfDzGznn6s8Oy2G0sDsdxSFj3scqABODmWVAI6PqOq2dBMIZpJlgF-RF0eSolY7BzjtshP1pg9mDLbuzBlj3YsgC22qpDH07pu_UW_dPISU8Fvh4BrKXV5rMtLmJy6GNtfLF-iv_L_wcXeKad</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19908030</pqid></control><display><type>article</type><title>Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wong, Joseph ; Brugger, Andrew ; Khare, Atul ; Chaubal, Mahesh ; Papadopoulos, Pavlos ; Rabinow, Barrett ; Kipp, James ; Ning, John</creator><creatorcontrib>Wong, Joseph ; Brugger, Andrew ; Khare, Atul ; Chaubal, Mahesh ; Papadopoulos, Pavlos ; Rabinow, Barrett ; Kipp, James ; Ning, John</creatorcontrib><description>There has been growing interest in nanoparticles as an approach to formulate poorly soluble drugs. Besides enhanced dissolution rates, and thereby, improved bioavailability, nanoparticles can also provide targeting capabilities when injected intravenously. The latter property has led to increased research and development activities for intravenous suspensions. The first intravenously administered nanoparticulate product, Abraxane® (a reformulation of paclitaxel), was approved by the FDA in 2006. Additional clinical trials have been conducted or are ongoing for multiple other indications such as oncology, infective diseases, and restenosis. This article reviews various challenges associated with developing intravenous nanosuspension dosage forms. In addition, various formulation considerations specific to intravenous nanosuspensions as well as reported findings from various clinical studies have been discussed.</description><identifier>ISSN: 0169-409X</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2007.11.008</identifier><identifier>PMID: 18343527</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Biological Availability ; Clinical Trials as Topic ; Drug Delivery Systems ; Drug Evaluation, Preclinical ; Extended release ; Humans ; Injections, Intravenous ; Insoluble drug delivery ; Intravenous injection ; Nanoparticles ; Pharmaceutical Preparations - administration & dosage ; Pharmaceutical Preparations - chemistry ; Poorly water-soluble drugs ; Safety ; Solubility ; Suspensions</subject><ispartof>Advanced drug delivery reviews, 2008-05, Vol.60 (8), p.939-954</ispartof><rights>2008 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-3dc1f9fe6e38499eb6cf86bd6441603f196ee0554dd92768ed7c40cdd739a7f3</citedby><cites>FETCH-LOGICAL-c482t-3dc1f9fe6e38499eb6cf86bd6441603f196ee0554dd92768ed7c40cdd739a7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169409X08000471$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18343527$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Joseph</creatorcontrib><creatorcontrib>Brugger, Andrew</creatorcontrib><creatorcontrib>Khare, Atul</creatorcontrib><creatorcontrib>Chaubal, Mahesh</creatorcontrib><creatorcontrib>Papadopoulos, Pavlos</creatorcontrib><creatorcontrib>Rabinow, Barrett</creatorcontrib><creatorcontrib>Kipp, James</creatorcontrib><creatorcontrib>Ning, John</creatorcontrib><title>Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>There has been growing interest in nanoparticles as an approach to formulate poorly soluble drugs. Besides enhanced dissolution rates, and thereby, improved bioavailability, nanoparticles can also provide targeting capabilities when injected intravenously. The latter property has led to increased research and development activities for intravenous suspensions. The first intravenously administered nanoparticulate product, Abraxane® (a reformulation of paclitaxel), was approved by the FDA in 2006. Additional clinical trials have been conducted or are ongoing for multiple other indications such as oncology, infective diseases, and restenosis. This article reviews various challenges associated with developing intravenous nanosuspension dosage forms. In addition, various formulation considerations specific to intravenous nanosuspensions as well as reported findings from various clinical studies have been discussed.</description><subject>Animals</subject><subject>Biological Availability</subject><subject>Clinical Trials as Topic</subject><subject>Drug Delivery Systems</subject><subject>Drug Evaluation, Preclinical</subject><subject>Extended release</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Insoluble drug delivery</subject><subject>Intravenous injection</subject><subject>Nanoparticles</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pharmaceutical Preparations - chemistry</subject><subject>Poorly water-soluble drugs</subject><subject>Safety</subject><subject>Solubility</subject><subject>Suspensions</subject><issn>0169-409X</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFrFDEYhoModq3-AQ-Skyg403xJJpMUL6WoLRQ8tIi3MJt8gSyzmTGZXem_N8su9GZPIcnzvfC9DyHvgbXAQF1s2sH73HLG-hagZUy_ICvQPW80N_IlWVXINJKZ32fkTSkbxoD3ir0mZ6CFFB3vVwTvd2XGVOKUCg1TpjEtedhjmnaFfrr99bk-bNAt9f-SXtGM-4h_6RSoxz2O07zFtHyhc0Y3xhTdMNIhefp0qeFuKW_JqzCMBd-dznPy8P3bw_VNc_fzx-311V3jpOZLI7yDYAIqFFoag2vlglZrr6QExUQAoxBZ10nvTd1Eo--dZM77XpihD-KcfDzGznn6s8Oy2G0sDsdxSFj3scqABODmWVAI6PqOq2dBMIZpJlgF-RF0eSolY7BzjtshP1pg9mDLbuzBlj3YsgC22qpDH07pu_UW_dPISU8Fvh4BrKXV5rMtLmJy6GNtfLF-iv_L_wcXeKad</recordid><startdate>20080522</startdate><enddate>20080522</enddate><creator>Wong, Joseph</creator><creator>Brugger, Andrew</creator><creator>Khare, Atul</creator><creator>Chaubal, Mahesh</creator><creator>Papadopoulos, Pavlos</creator><creator>Rabinow, Barrett</creator><creator>Kipp, James</creator><creator>Ning, John</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7U5</scope><scope>L7M</scope><scope>7X8</scope></search><sort><creationdate>20080522</creationdate><title>Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects</title><author>Wong, Joseph ; Brugger, Andrew ; Khare, Atul ; Chaubal, Mahesh ; Papadopoulos, Pavlos ; Rabinow, Barrett ; Kipp, James ; Ning, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-3dc1f9fe6e38499eb6cf86bd6441603f196ee0554dd92768ed7c40cdd739a7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Biological Availability</topic><topic>Clinical Trials as Topic</topic><topic>Drug Delivery Systems</topic><topic>Drug Evaluation, Preclinical</topic><topic>Extended release</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Insoluble drug delivery</topic><topic>Intravenous injection</topic><topic>Nanoparticles</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pharmaceutical Preparations - chemistry</topic><topic>Poorly water-soluble drugs</topic><topic>Safety</topic><topic>Solubility</topic><topic>Suspensions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Joseph</creatorcontrib><creatorcontrib>Brugger, Andrew</creatorcontrib><creatorcontrib>Khare, Atul</creatorcontrib><creatorcontrib>Chaubal, Mahesh</creatorcontrib><creatorcontrib>Papadopoulos, Pavlos</creatorcontrib><creatorcontrib>Rabinow, Barrett</creatorcontrib><creatorcontrib>Kipp, James</creatorcontrib><creatorcontrib>Ning, John</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Joseph</au><au>Brugger, Andrew</au><au>Khare, Atul</au><au>Chaubal, Mahesh</au><au>Papadopoulos, Pavlos</au><au>Rabinow, Barrett</au><au>Kipp, James</au><au>Ning, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2008-05-22</date><risdate>2008</risdate><volume>60</volume><issue>8</issue><spage>939</spage><epage>954</epage><pages>939-954</pages><issn>0169-409X</issn><eissn>1872-8294</eissn><abstract>There has been growing interest in nanoparticles as an approach to formulate poorly soluble drugs. Besides enhanced dissolution rates, and thereby, improved bioavailability, nanoparticles can also provide targeting capabilities when injected intravenously. The latter property has led to increased research and development activities for intravenous suspensions. The first intravenously administered nanoparticulate product, Abraxane® (a reformulation of paclitaxel), was approved by the FDA in 2006. Additional clinical trials have been conducted or are ongoing for multiple other indications such as oncology, infective diseases, and restenosis. This article reviews various challenges associated with developing intravenous nanosuspension dosage forms. In addition, various formulation considerations specific to intravenous nanosuspensions as well as reported findings from various clinical studies have been discussed.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>18343527</pmid><doi>10.1016/j.addr.2007.11.008</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-409X |
| ispartof | Advanced drug delivery reviews, 2008-05, Vol.60 (8), p.939-954 |
| issn | 0169-409X 1872-8294 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69141129 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Biological Availability Clinical Trials as Topic Drug Delivery Systems Drug Evaluation, Preclinical Extended release Humans Injections, Intravenous Insoluble drug delivery Intravenous injection Nanoparticles Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - chemistry Poorly water-soluble drugs Safety Solubility Suspensions |
| title | Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A19%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Suspensions%20for%20intravenous%20(IV)%20injection:%20A%20review%20of%20development,%20preclinical%20and%20clinical%20aspects&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Wong,%20Joseph&rft.date=2008-05-22&rft.volume=60&rft.issue=8&rft.spage=939&rft.epage=954&rft.pages=939-954&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2007.11.008&rft_dat=%3Cproquest_cross%3E19908030%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19908030&rft_id=info:pmid/18343527&rft_els_id=S0169409X08000471&rfr_iscdi=true |